• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

3,5-二乙酰基-1,4-二氢吡啶:肿瘤细胞中的合成与多药耐药逆转

3,5-diacetyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells.

作者信息

Shah A, Gaveriya H, Motohashi N, Kawase M, Saito S, Sakagami H, Satoh K, Tada Y, Solymosi A, Walfard K, Molnar J

机构信息

Department of Chemistry, Saurashtra University, Rajkot, India.

出版信息

Anticancer Res. 2000 Jan-Feb;20(1A):373-7.

PMID:10769682
Abstract

Eleven 4-phenyl-3,5-diacetyl-1,4-dihydropyridines (AcDHPs) [G1-11] substituted at the phenyl ring were synthesized and compared for their cytotoxic activity and multidrug resistance (MDR)-reversing activity in in vitro assay systems. Among them, compound [G7] showed the highest cytotoxic activity against human promyelocytic leukemia HL-60 and human squamous cell carcinoma HSC-2 cells. However, no compounds tested produced radicals at pH 7.4-12.5. The activity of P-glycoprotein (Pgp) responsible for MDR in tumor cells was reduced by compounds [G2, 3, 6, 5, 8, 1, 11], verapamil [VP] and nifedipine [NP]. However, compounds [G4, 7, 10] were hardly active while G9 did not show a MDR reversing effect at 2.0-20.0 micrograms/mL. These data show a relationship between chemical structures and MDR-reversing effect on tumor cells.

摘要

合成了11种在苯环上有取代基的4-苯基-3,5-二乙酰基-1,4-二氢吡啶(AcDHPs)[G1 - 11],并在体外分析系统中比较了它们的细胞毒性活性和多药耐药性(MDR)逆转活性。其中,化合物[G7]对人早幼粒细胞白血病HL - 60和人鳞状细胞癌HSC - 2细胞显示出最高的细胞毒性活性。然而,在pH 7.4 - 12.5条件下,所测试的化合物均未产生自由基。负责肿瘤细胞中MDR的P - 糖蛋白(Pgp)的活性被化合物[G2、3、6、5、8、1、11]、维拉帕米[VP]和硝苯地平[NP]降低。然而,化合物[G4、7、10]几乎没有活性,而G9在2.0 - 20.0微克/毫升时未显示出MDR逆转作用。这些数据表明了化学结构与对肿瘤细胞的MDR逆转作用之间的关系。

相似文献

1
3,5-diacetyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells.3,5-二乙酰基-1,4-二氢吡啶:肿瘤细胞中的合成与多药耐药逆转
Anticancer Res. 2000 Jan-Feb;20(1A):373-7.
2
3,5-dibenzoyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells.3,5-二苯甲酰基-1,4-二氢吡啶:肿瘤细胞中的合成与多药耐药逆转
Bioorg Med Chem. 2002 Apr;10(4):1051-5. doi: 10.1016/s0968-0896(01)00363-7.
3
Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.新型1,4 - 二氢吡啶对人癌细胞的细胞毒性及多药耐药逆转活性
Eur J Pharmacol. 2015 Jan 5;746:233-44. doi: 10.1016/j.ejphar.2014.10.058. Epub 2014 Nov 14.
4
Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR.二氢吡啶类与非典型多药耐药:设计针对典型和非典型多药耐药的通用逆转剂的新视角。
Bioorg Med Chem. 2008 Sep 15;16(18):8329-34. doi: 10.1016/j.bmc.2008.07.025. Epub 2008 Jul 18.
5
Reversal of multidrug resistance in cancer cells by novel asymmetrical 1,4-dihydropyridines.新型不对称 1,4-二氢吡啶逆转肿瘤细胞多药耐药。
Arch Pharm Res. 2013 Nov;36(11):1392-402. doi: 10.1007/s12272-013-0149-8. Epub 2013 May 15.
6
Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.与维拉帕米和阿霉素相比,评估新合成的二氢吡啶衍生物对T47D亲本细胞系和耐药细胞系的体外抗癌作用。
Cell Biol Toxicol. 2008 Apr;24(2):165-74. doi: 10.1007/s10565-007-9026-x. Epub 2007 Sep 6.
7
In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
J Exp Ther Oncol. 1996 Jan;1(1):23-9.
8
Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.FG020318在体外和体内逆转P-糖蛋白介导的多药耐药性。
J Pharm Pharmacol. 2004 Aug;56(8):1061-6. doi: 10.1211/0022357043879.
9
Evaluation of Novel Benzo-annelated 1,4-dihydropyridines as MDR Modulators in Cancer Cells.新型苯并稠合1,4-二氢吡啶作为癌细胞中多药耐药调节剂的评估
Anticancer Agents Med Chem. 2024;24(14):1047-1055. doi: 10.2174/0118715206314406240502054139.
10
Synthesis and structure--activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance.新型二氢吡啶衍生物的合成及其克服多药耐药性的构效关系分析
Bioorg Med Chem Lett. 2001 Jan 22;11(2):275-7. doi: 10.1016/s0960-894x(00)00651-x.

引用本文的文献

1
Synthesis of novel 1,8-acridinediones derivatives: Investigation of MDR reversibility on breast cancer cell lines T47D and tamoxifen-resistant T47D.新型1,8 - 吖啶二酮衍生物的合成:对乳腺癌细胞系T47D和他莫昔芬耐药的T47D的多药耐药逆转研究。
Res Pharm Sci. 2015 May-Jun;10(3):214-21.
2
Diisopropyl 1-(4-meth-oxy-phen-yl)-2,6-dimethyl-4-(3-nitro-phen-yl)-1,4-dihydro-pyridine-3,5-dicarboxyl-ate.1-(4-甲氧基苯基)-2,6-二甲基-4-(3-硝基苯基)-1,4-二氢吡啶-3,5-二羧酸二异丙酯
Acta Crystallogr Sect E Struct Rep Online. 2011 Nov;67(Pt 11):o2979. doi: 10.1107/S1600536811042073. Epub 2011 Oct 22.
3
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.
ABC转运蛋白作为多药耐药机制以及针对其逆转的化学增敏剂的开发。
Cancer Cell Int. 2005 Oct 4;5:30. doi: 10.1186/1475-2867-5-30.
4
3,5-Dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7) as a new multidrug resistance reverting agent devoid of effects on vascular smooth muscle contractility.3,5-二苯甲酰基-4-(3-苯氧基苯基)-1,4-二氢-2,6-二甲基吡啶(DP7)作为一种新型多药耐药逆转剂,对血管平滑肌收缩性无影响。
Br J Pharmacol. 2004 Feb;141(3):415-22. doi: 10.1038/sj.bjp.0705635. Epub 2004 Jan 12.